Blood Transfusion Management in Patients With Mitral Valve Replacement in China

Study Overview
=================
Brief Summary
-----------------
The evaluation uses ΔHb as an independent factor combined with artificial intelligence (AI) to predict its impact on the prognosis and blood transfusion of patients undergoing cardiac surgery, thereby guiding perioperative clinical blood use and improving patient prognosis.

Detailed Description
-----------------
Select 8 hospitals to form a multi-center team, and enter the keyword mitral valve replacement in the case system of 8 hospitals to collect information on 2000 heart surgery patients. Mainly collect information on preoperative, intraoperative and postoperative test indexes (blood routine, liver and kidney function, coagulation function, blood gas), cardiac color Doppler, blood transfusion and prognosis of patients undergoing cardiac surgery, using statistical methods for analysis. Identify key observations. Gradually incorporate and exclude data, and use statistical methods to conduct preliminary analysis on the collected data. The AI prediction model was established by machine learning algorithm to predict intraoperative blood transfusion, verify the specificity and sensitivity of the blood transfusion prediction model, and scientifically guide clinical blood use.

Official Title
-----------------
Establishment of AI Prediction Model of Blood Transfusion Management in Patients With Mitral Valve Replacement

Conditions
-----------------
Mitral Valve Replacement, Transfusion Reaction, Blood Transfusion Complication

Intervention / Treatment
-----------------
* Procedure: Mitral valve replacement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing mitral valve replacement surgery; Age 18-75 years old; 48h biochemical indicators before surgery, blood general indicators, coagulation indicators are complete. Exclusion Criteria: Lack of necessary tests and patient test information is not detailed, blood transfusion information is not detailed; The blood transfusion information is not detailed in the same period as other cardiac operations (such as aortic valve surgery, coronary artery bypass grafting, etc.), but the tricuspid valvuloplasty is not ruled out at the same time; Heart surgery or emergency surgery again.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Groups/Cohorts<br>1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete. | Procedure: Mitral valve replacement<br>* Blood transfusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | The mortality during and after hospitalization | through study completion, an average of 2 year | 
| Intraoperative blood transfusion | The amount of intraoperative blood component input | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mitral valve replacement, Predictive Model, Blood Transfusion, Perioperative period